Why the study?
The arrhythmogenic property of ciprofloxacin is uncertain due to limited reported cases and possible interactions with other arrhythmogenic drugs.
Does oral ciprofloxacin increase the risk of Torsades de pointes and cardiac arrhythmias?
Case Report (n=1)
Does oral ciprofloxacin increase the risk of Torsades de pointes and cardiac arrhythmias?
Answers are grounded in this paper and cite their sources.
Ciprofloxacin may possess arrhythmogenic properties leading to Torsades de pointes, particularly through pharmacokinetic interactions with other drugs in patients with concomitant risk factors.
Torsades de pointes (Tdp) is a polymorphic form of ventricular tachycardia and a life-threatening event. A variety of non-cardiovascular drugs, including fluoroquinolone antibiotics, have been shown to possess arrhythmogenic properties. However, only 25 cases of ventricular tachycardia associated with the use of ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin have been reported in the United States between 1996 and 2000, with ciprofloxacin being involved in two cases. Thus, it has been argued that the arrhythmogenic property of ciprofloxacin may derive from its interaction with other potentially arrhythmogenic drugs. We report: (i) a case of torsades de pointes (Tdp) associated with oral ciprofloxacin in a patient with concomitant risk factors and (ii) a review of the literature on pharmacokinetic interactions involving ciprofloxacin resulting in cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Haring et al. (2012) conducted a case report in Torsades de pointes (Tdp) (n=1). Oral ciprofloxacin was evaluated on Torsades de pointes (Tdp).
Synapse has enriched 10 related papers. Consider them for comparative context: